Editas director granted 51,700 stock options

Editas Medicine, Inc. director David Scadden received a grant of stock options covering 51,700 shares of common stock.

Rhea-AI Filing Summary

Editas Medicine, Inc. director David Scadden received a grant of stock options covering 51,700 shares of common stock. The options have an exercise price of $2.55 per share and expire on June 16, 2036. They were granted on June 17, 2026 and are scheduled to vest in full on June 17, 2027. Following this grant, Scadden holds 51,700 stock options directly.

Insider Trade Summary

Grant/Award: 51,700 shares

Grant/Award 1 txn

Insider Scadden David

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	51,700	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy) — 51,700 contracts (Direct)

Footnotes (1)

1. F1. This option was granted on June 17, 2026 and is scheduled to vest in full on June 17, 2027.

Key Figures

Stock options granted: 51,700 options Exercise price: $2.55 per share Expiration date: June 16, 2036 +2 more

5 metrics

Stock options granted 51,700 options Grant on June 17, 2026 to director

Exercise price $2.55 per share Stock option strike price

Expiration date June 16, 2036 Option term end date

Underlying shares 51,700 shares Common stock underlying options

Post-grant option holdings 51,700 options Total options held following transaction

Key Terms

Stock Option (right to buy), Grant, award, or other acquisition, exercise price, vest in full

4 terms

Stock Option (right to buy) financial

"security_title: "Stock Option (right to buy)""

Grant, award, or other acquisition financial

"transaction_code_description: "Grant, award, or other acquisition""

exercise price financial

"conversion_or_exercise_price: "2.5500""

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vest in full financial

"scheduled to vest in full on June 17, 2027"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Editas Medicine (EDIT) director David Scadden receive in this Form 4?

Director David Scadden received a grant of stock options for 51,700 shares of Editas Medicine common stock. These options represent a compensation award rather than an open-market share purchase or sale, and are recorded as a derivative security on the Form 4.

What is the exercise price of David Scadden’s Editas Medicine stock options?

The stock options granted to David Scadden have an exercise price of $2.55 per share. This means he can buy Editas Medicine common stock at $2.55 once the options vest, regardless of the market price at that time.

When do David Scadden’s Editas Medicine stock options vest and expire?

The options were granted on June 17, 2026 and are scheduled to vest in full on June 17, 2027. They have an expiration date of June 16, 2036, giving a long window to exercise after vesting, subject to continued service and plan terms.

How many Editas Medicine options does David Scadden hold after this grant?

After this grant, David Scadden holds 51,700 stock options directly according to the Form 4. These options each relate to one share of Editas Medicine common stock and reflect his derivative position following the reported compensation award.

Does this Editas Medicine Form 4 show any stock being bought or sold on the market?

No open-market buys or sells are reported here; the filing shows a grant of stock options coded as an acquisition (A). This is a compensation-related award, not a market transaction involving existing Editas Medicine shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/22/2026 - 04:29 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Scadden David

(Last) (First) (Middle)

C/O EDITAS MEDICINE, INC.,

11 HURLEY ST.

(Street)

CAMBRIDGE MASSACHUSETTS 02141

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Editas Medicine, Inc. [ EDIT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/17/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$2.55	06/17/2026		A		51,700		(1)	06/16/2036	Common Stock	51,700	$0	51,700	D

Explanation of Responses:

1. This option was granted on June 17, 2026 and is scheduled to vest in full on June 17, 2027.

Remarks:

	/s/ David Scadden	06/22/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)